학술논문
Safety and immunogenicity of SpikoGen®, an Advax-CpG55.2-adjuvanted SARS-CoV-2 spike protein vaccine: a phase 2 randomized placebo-controlled trial in both seropositive and seronegative populations
Document Type
Article
Author
Source
In Clinical Microbiology and Infection September 2022 28(9):1263-1271
Subject
Language
ISSN
1198-743X